Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system

Neuroscience Letters
Xiaoju WangGuanghui Wang

Abstract

TAR DNA-binding protein-43 (TDP-43) is a nuclear protein functioning in the regulation of transcription and mRNA splicing. TDP-43 is accumulated in ubiquitinated inclusions in frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS) diseased brains. However, the pathways involved in the clearance of TDP-43 and its pathogenic form (TDP-25), a truncated form of TDP-43, are still not elucidated. In this study, we demonstrated that the protein levels of TDP-43 and TDP-25 were increased in cells treated with a proteasome inhibitor, MG132, or an autophagy inhibitor, 3-MA, whereas, they were decreased in cells treated with an enhancer of autophagy, trehalose. Furthermore, more protein level changes of TDP-25 than TDP-43 were observed in cells treated with above inhibitors or enhancer. Thus, our data suggest that TDP-43 and TDP-25 are degraded by both proteasome and autophagy with TDP-25 being more regulated.

References

Mar 27, 2001·Nature Reviews. Molecular Cell Biology·A M Weissman
Jun 17, 2004·Journal of Neurochemistry·Makoto UrushitaniRyosuke Takahashi
Dec 22, 2006·The Journal of Biological Chemistry·Sovan SarkarDavid C Rubinsztein
Jan 15, 2008·Cell·Beth Levine, Guido Kroemer
Sep 23, 2008·Future Neurology·Salvatore J Cherra, Charleen T Chu
Jan 24, 2009·The Journal of Biological Chemistry·Lionel M IgazVirginia M-Y Lee
Feb 17, 2009·The Journal of Biological Chemistry·Atsushi IwataShoji Tsuji
Apr 21, 2009·Autophagy·Derek NarendraRichard J Youle
Apr 23, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yong-Jie ZhangLeonard Petrucelli

❮ Previous
Next ❯

Citations

Dec 1, 2011·Nature Reviews. Neuroscience·Edward B LeeJohn Q Trojanowski
Nov 5, 2011·The Journal of Biological Chemistry·Jayarama Krishnan BoseC-K James Shen
Oct 26, 2012·The Journal of Biological Chemistry·Yoshitaka TashiroRyosuke Takahashi
Jun 22, 2010·Antioxidants & Redox Signaling·Melissa NassifClaudio Hetz
Apr 20, 2010·Human Molecular Genetics·Clotilde Lagier-TourenneDon W Cleveland
Aug 1, 2013·Human Molecular Genetics·Jonathan Janssens, Christine Van Broeckhoven
Sep 25, 2012·Molecular Neurodegeneration·Keiichi InoueAsa Abeliovich
Jun 4, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Gillian P RitsonJ Paul Taylor
Jul 18, 2014·Alzheimer's Research & Therapy·Faisal FectoTeepu Siddique
Jun 30, 2014·Nature Chemical Biology·Sami J BarmadaSteven Finkbeiner
Dec 3, 2014·Neurochemistry International·Mariarita GalbiatiAngelo Poletti
Feb 3, 2016·Molecular and Cellular Neurosciences·Maria Sara Cipolat MisStefania Corti
Apr 27, 2012·Trends in Biochemical Sciences·Emanuele Buratti, Francisco E Baralle
Oct 27, 2011·Wiley Interdisciplinary Reviews. RNA·Keith A HansonRandal S Tibbetts
Dec 14, 2011·Brain Pathology·Sheng ChenWeidong Le
Jul 23, 2011·The FEBS Journal·Fabienne C Fiesel, Philipp J Kahle
Jul 16, 2014·Acta Neuropathologica Communications·Yoshinori TanakaMasugi Nishihara
Jul 2, 2015·Human Molecular Genetics·Ching-Chieh ChouWilfried Rossoll
Apr 23, 2015·Neurotoxicology·Emma Muñoz-SáezBegoña Gómez Miguel
Jul 26, 2011·Biochimica Et Biophysica Acta·Kunitoshi YamanakaTeru Ogura
Nov 20, 2010·Current Opinion in Cell Biology·Fiona M MenziesDavid C Rubinsztein
Sep 16, 2011·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Gessica SalaCarlo Ferrarese
Jul 26, 2012·The International Journal of Neuroscience·Cheng-yuan SongBei-sha Tang
Mar 22, 2014·Expert Opinion on Therapeutic Targets·Mauricio BudiniEmanuele Buratti
Feb 6, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Emma L ScotterChristopher E Shaw
Mar 21, 2015·Human Molecular Genetics·Mattéa J FinelliKay E Davies

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.